Aspire Biopharma Holdings (ASBP) Restructuring Costs (2024 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly Restructuring Costs came in at $229418.0 in Q2 2026, down 42.02% year-over-year from $395692.0 in Q2 2025, and down 42.02% quarter-over-quarter from $395692.0 in Q2 2025.
Powered by 
Analysis
Aspire Biopharma Holdings (ASBP) Restructuring Costs (2024 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Restructuring Costs for 3 consecutive years, with $229418.0 the latest figure, recorded in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | Aspire Biopharma Holdings | 64.13 Mn | 51.96 Mn | -30,086.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 229,418.00 |
| Jun 30, 2025 | 395,692.00 |
| Jun 30, 2024 | 86,423.00 |